Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05049668
Enrolling by invitation Observational

RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial

NCT05049668 · tracked via the Priya Life Science France tracker
Sponsor
European Society for Blood and Marrow Transplantation
Phase
Observational
Started
2021-10
Last updated
2021-09-27

Condition(s) studied

Severe Aplastic Anemia

Investigational drug(s) / intervention(s)

ATGAM plus CsA with or without Eltrombopag

ATGAM plus CsA with or without Eltrombopag: Standard treatment with or without Eltrombopag

Study summary

After exiting the RACE trial (NCT02099747) patients will be invited to participate in this long term follow-up study

Eligibility

Sex
All
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Subject participated in the RACE trial (NCT02099747, EudraCT number: 2014-000363-40) during which patient received ATGAM, Cyclosporine A with or without Eltrombopag. 2. Subject has provided informed consent to participate in long-term data collection Exclusion Criteria: None

Primary outcome measure(s)

  • Failure Free Survival — 15 years
    Failure Free Survival, where treatment failure is defined as one or more of the following: death, relapse, malignant clonal evolution, need for further (e.g. transplant)

Trial sites (1)

FacilityCityRegionStatus
Hospital St. Louis Paris France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05049668 on ClinicalTrials.gov ↗ ← All trials in France